Crizotinib supported for ALK-positive NSCLC patients with brain metastases
Treatment with the tyrosine kinase inhibitor crizotinib results in improved intracranial disease control relative to chemotherapy in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer, suggest results published in the Journal of Clinical Oncology.
Source: MedWire News - Category: Consumer Health News Tags: Non-small-cell lung cancer Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Health | Lung Cancer | Lymphoma | Neurology | Non-Small Cell Lung Cancer